for Lovenox(R) versus unfractionated heparin in patients with acute ST-segment elevation myocardial infarction.
Lantus(R), the world's leading insulin brand, continues to record excellent performances, with net sales up 34.6% in the United States, 21.2% in Europe and 41.7% in the rest of the world. SoloSTAR(R), a new disposable pen used to administer Lantus(R) and/or the rapid-acting insulin Apidra(R), is now available in most major European countries. In France, one of the first European countries where Lantus(R) SoloSTAR(R) was made available, the introduction of this new pen led to an acceleration in sales of Lantus(R) during the third quarter. In the United States, Lantus(R) SoloSTAR(R) -- launched in July -- is supporting growth in sales of Lantus(R).
Taxotere(R) posted strong third-quarter growth of 18.9% in Europe and 15.2% in "Other countries." In the United States, net sales of the product rose by 8.0%.
In early September, efficacy results from a meta-analysis of individual patient data called DOCMA-LC (DOCetaxel Meta-Analysis in Lung Cancer) were presented at the 12th World Conference on Lung Cancer in Seoul. This meta- analysis included 2,867 patients from seven clinical trials, and demonstrated a significant overall survival benefit for Taxotere(R) over vinca-alkaloid- based regimens as a first-line treatment for patients with advanced non small cell lung cancer.
Following a priority review, the U.S. Food and Drug Administration
(FDA) approved Taxotere(R) in association with cisplatin and 5-fluorouracil
for the induction (neo-adjuvant) therapy of patients with locally-advanced
squamous cell carcinoma of the head and neck prior to chemoradiotherapy and
surgery. In October, the Committee for Medicinal Produc
Copyright©2007 PR Newswire.
All rights reserved